SEARCH

SEARCH BY CITATION

References

  • Anders, M. W., Sunram, J. M. & Wilkinson, C. F. (1984). Mechanism of the metabolism of 1,3-benzodioxoles to carbon monoxide. Biochem. Pharmac., 33, 577580.
  • Brosen, K., Gram, L. F. & Kragh-Sorensen, P. (1991). Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metaboliser of sparteine, debrisoquine and mephenytoin. Ther. Drug Monit., 13, 177182.
  • Eichelbaum, M., Spannbrucker, N. & Dengler, H. J. (1978). A probably genetic defect of the metabolism of sparteine. In Biological oxidation of nitrogen, ed. Gorrod, J. W., pp. 113118. Elsevier/North Holland Biomedical Press.
  • Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P. & Meyer, U. A. (1988). Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442446.
  • Haddock, R. E., Johnson, A. M., Langley, P. F., Nelson, D. R., Pope, J. A., Thomas, D. R. & Woods, F. R. (1989). Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr. Scand., 80 (supp. 350), 2426.
  • Kaye, C. M., Haddock, R. E., Langley, P. F., Mellows, G. Tasker, T. C. G., Zussman, B. D. & Greb, W. H. (1989). A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand., 80 (supp. 350), 6075.
  • Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R. & Smith, R. L. (1977). Polymorphic hydroxylation of debrisoquine in man. Lancet, ii, 584586.
  • Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T., & Woods, H. F. (1988). Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human microsomes. J. Pharmac. exp. Ther., 247, 242247.
  • Sindrup, S. H., Brosen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G. & Zussman, B. D. (1992). The relationship between paroxetine and sparteine oxidation polymorphism. Clin. Pharmac. Ther., (in press).
  • Tucker, G. T., Silas, J. H., Iyan, A. O., Lennard, M. S. & Smith, A. J. (1977). Polymorphic hydroxylation of debrisoquine. Lancet, ii, 718.